

## Medical Preferred Drug List (Medicaid) – July 2026

Prepared for CA, IA, ID, NM, SC, UT, and WI

Drug Class	Non-Preferred Product(s)	Preferred Product(s)
Alpha-1 Antitrypsin Deficiency	Aralast® Glassia® Zemaira® (Alpha-1-Proteinase Inhibitor)	Prolastin C® (Alpha-1-Proteinase Inhibitor)
Antiviral-MAB-RSV		Beyfortus® (nirsevimab-alip) Enflonia™ (clesrovimab-cfor)
Autoimmune – Infliximab/Remicade	Remicade® (infliximab) Infliximab (unbranded) Renflexis® (infliximab-abda) Zymfentra® (infliximab-dyyb)	Avsola® (infliximab-axxq) Inflectra® (infliximab-dyyb)
Denosumab/Prolia/Xgeva Biosimilars	Prolia/Xgeva® (denosumab) Aukelso/Bosaya® (denoxumab-kyqq) Bomynta/Conexxence® (denosumab-bnht) Not covered: Ospomyv/Xbryk® (denosumab-dssb)	Bildyos/Bilprevda®(denosumab-nxxp) Jubbonti/Wyost®(denosumab-bbdz) Stoboclo/Osenvelt®(denosumab-bmwo)
*Hematologic, Colony Stimulating Factors – Short Acting	Granix® (tbo-filgrastum) Leukine®(sargramostim) Neupogen® (filgrastim) Nivestym® (filgrastim-aafi) Nypozi® (filgrastim)	Zarxio® (filgrastim-sndz)
*Hematologic, Colony Stimulating Factors – Long Acting	Ziextenzo® (pegfilgrastim-bmez) Udenyca® (pegfilgrastim-cbqv) Nyvepria™(pegfilgrastim-apgf) Fylnetra®(pegfilgrastim-pbbk) Rolvedon®(eflapergrastim-xnst) Ryzneuta®(efbemalenograstim alfa vuxw) Stimufend®(pegfilgrastim-fpgk)	Fulphila™ (pegfilgrastim-jmdb) Neulasta® (pegfilgrastim)
Heme, IV Iron	Injectafer® (ferric carboxymaltose) Monoferic® (ferric derisomaltose)	Ferrlecit® (sodium ferric gluconate) Infed® (iron dextran) Venofer® (iron sucrose) Feraheme® (ferumoxytol)
Immune Globulin – IV	Asceniv® (immune globulin) Carimune® (immune globulin) Gammaplex® (immune globulin) Panzyga® (immune globulin) Vivaglobin® (immune globulin)	Bivigam® (immune globulin) Flebogamma® (immune globulin) Gammagard® (immune globulin) Gammagard S/D® (immune globulin) Gamunex-C® (immune globulin) Gammaked® (immune globulin) Octagam® (immune globulin) Privigen® (immune globulin)

\*In specific states Evolent's preferred drug list will apply prior to Molina's. See [New Century Health's Website](#) for the Evolent ODL (oncology drug list). Non-preferred product(s) are only available if process exception criteria are met. This list indicates the common uses for which the drug is prescribed. \*\*Some medicines are prescribed for more than one condition. This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with Molina Healthcare, Inc. Listed products are for informational purposes only and are not intended to replace the clinical judgment of the prescriber. Listed therapeutic classes and specific drug preferred designations are subject to change based on new drug launches, product approvals, drug withdrawals and other market changes.

Drug Class	Non-Preferred Product(s)	Preferred Product(s)
Lysosomal Storage Disorders – Gaucher Disease	VPRIV® (velaglucerase alfa) Elelyso® (taliglucerase alfa)	Cerezyme® (imiglucerase)
Multiple Sclerosis (Infused)	Lemtrada® (alemtuzumab) Briumvi (ublituximab-xiyy) Ocrevus Zunovo® (ocrelizumab-hyaluronidase) Tyruko® (natalizumab)	Tysabri® (natalizumab) Ocrevus® (ocrelizumab)
Myasthenia Gravis/Paroxysmal Nocturnal Hemoglobinuria (PNH)	Empaveli® (pegcetaclopan) Soliris® (eculizumab) Ultomiris® (Ravulizumab-cwrz)	Bkemv® (eculizumab-aeab) Epysqli® (eculizumab-aagh)
Osteoarthritis, Viscosupplements	Gelsyn-3® (sodium hyaluronate) GenVisc® 850 (sodium hyaluronate) Hyalgan® (1% sodium hyaluronate) Hymovis (sodium hyaluronate) Orthovisc® (1% sodium hyaluronate) Supartz® FX (1% sodium hyaluronate) SynoJoynt® (1% sodium hyaluronate) Synvisc® (hylan (Avian) 8 mg/mL) Triluron® (sodium hyaluronate) TriVisc® (sodium hyaluronate) Visco-3® (1% sodium hyaluronate)	Euflexxa® (1% sodium hyaluronate)
Oncology – IV with SC Formulations	Darzalex Faspro® (daratumumab-hyaluronidase-fihj) Keytruda Qlex™ (pembrolizumab-berahyaluronidase alfa-pmph) Opdivo Qvantig™ (nivolumab-hyaluronidase-nvyh) Tecentriq Hybreza™ (atezolizumab-hyaluronidase-tqrs) ***Herceptin Hylecta™ & Rituxan Hycela® (refer to their sections for preferred products)	Darzalex® (daratumumab) Keytruda® (pembrolizumab) Opdivo® (nivolumab) Tecentriq® (atezolizumab)
*Oncology	Alymsys® (bevacizumab-maly) **Avastin® (bevacizumab) Vegzelma® (bevacizumab-adcd)	Mvasi™ (bevacizumab-awwb) Zirabev® (bevacizumab-bvzr)
	Herceptin® (trastuzumab) Herceptin Hycelta™ (trastuzumab and hyaluronidase-oysk) Hercessi® (trastuzumab-strf) Herzuma® (trastuzumab-pkrb) Ogivri™ (trastuzumab-dkst) Ontruzant® (trastuzumab-dttb) Trazimera™ (trastuzumab-qyyp)	***Kanjinti™ (trastuzumab-anns)
*Rituximab	Riabni™ (rituximab-arrx) Rituxan® (rituximab) Rituxan Hycela® (rituximab-hyaluronidase)	***Ruxience® (rituximab-pvvr) ***Truxima® (rituximab-abbs)

\*In specific states Evolent's preferred drug list will apply prior to Molina's. See [New Century Health's Website](#) for the Evolent ODL (oncology drug list). Non-preferred product(s) are only available if process exception criteria are met. This list indicates the common uses for which the drug is prescribed. \*\*Some medicines are prescribed for more than one condition. This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with Molina Healthcare, Inc. Listed products are for informational purposes only and are not intended to replace the clinical judgment of the prescriber. Listed therapeutic classes and specific drug preferred designations are subject to change based on new drug launches, product approvals, drug withdrawals and other market changes. \*\*\*See Rituximab & Trastuzumab sections.



Drug Class	Non-Preferred Product(s)	Preferred Product(s)
Retinal Disorders (Eye)	Pavblu® (aflibercept) Enzeevu® (aflibercept) Ahzantive® (aflibercept) Opuviz® (aflibercept) Byooviz® (ranibizumab) Cimerli® (ranibizumab-eqrn) Beovu® (brolucizumab-dbll) Macugen® (pegaptanib) Susvimo™ (ranibizumab) Vabysmo™ (faricimab-svoa) Visudyne® (verteporfin)	1a – Preferred overall: <ul style="list-style-type: none"> <li>• **Avastin® (bevacizumab)</li> </ul> 1b - Preferred over ranibizumab biosimilars & Eylea®: <ul style="list-style-type: none"> <li>• Lucentis® (ranibizumab)</li> </ul>
		2 - Preferred over aflibercept biosimilars: <ul style="list-style-type: none"> <li>• Eylea® (aflibercept)</li> </ul>
Tocilizumab/Actemra Biosimilars	Actemra® (tocilizumab) IV Avtozma® (tocilizumab-anoh)	Tofidence® (tocilizumab-bavi) Tyenne® (tocilizumab-aazg)
Ustekinumab/Stelara Biosimilars	Stelara® (ustekinumab) SC/IV Imuldosa® (Ustekinumab) Otulfi® (Ustekinumab) Steqeyma® (Ustekinumab) Wezlana® (ustekinumab) SC/IV	Pyzchiva® (Ustekinumab) SC/IV Yesintek® (ustekinumab-kfce) SC/IV

\*In specific states Evolent's preferred drug list will apply prior to Molina's. See [New Century Health's Website](#) for the Evolent ODL (oncology drug list). Non-preferred product(s) are only available if process exception criteria are met. This list indicates the common uses for which the drug is prescribed. \*\*Some medicines are prescribed for more than one condition. This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with Molina Healthcare, Inc. Listed products are for informational purposes only and are not intended to replace the clinical judgment of the prescriber. Listed therapeutic classes and specific drug preferred designations are subject to change based on new drug launches, product approvals, drug withdrawals and other market changes. \*\*\*See Rituximab & Trastuzumab sections.

